PubMed Health⌕ Search

Biomedical subjects

M A Goldsmith

Publications and source records attributed to M A Goldsmith.

At least 19 recordsLinked to original sources
PubMed1990

A transfected human muscarinic receptor fails to substitute for the T cell antigen receptor complex in CD2-initiated signal transduction.

Several T cell surface molecules can activate signal transduction pathways that lead to T cell activation. Like the T cell antigen receptor (TCR), several other molecules, including the sheep erythrocyte receptor CD2, are able to activate the phosphatidylinositol (PI) signal transduction pathway upon stimulation with appropriate agonists. However, CD2-initiated activation of this pathway is dependent on the functional expression of the TCR. Since the T cell does not express other known receptors that activate the PI pathway independent of the TCR, the specificity of the CD2 requirement for a functional TCR is not known. To evaluate the specificity of this requirement, we examined the functional capacity of CD2 to activate the PI pathway in a TCR-deficient cell which had been transfected with a heterologous receptor, the human muscarinic subtype 1 receptor (HM1). HM1 is a member of the cholinergic family of receptors and is known to activate the PI pathway. HM1 can function in the absence of the TCR in a Jurkat-derived T cell host. Here we demonstrate through calcium fluorimetry and PI metabolism assays that HM1 is unable to substitute functionally for the TCR in CD2-initiated signal transduction. These results suggest a specific functional interaction between CD2 and the TCR in CD2-mediated activation of the PI pathway in T cells.

Antigens, Differentiation, T-Lymphocyte↗
PubMed1989

Function of a heterologous muscarinic receptor in T cell antigen receptor signal transduction mutants.

Previously we have described a system of somatic cell genetics (J.CaM1 and J.CaM2) for analyzing signal transduction via the T cell antigen receptor complex (CD3/Ti). Here we describe a third mutant, J.CaM3, which also expresses high levels of receptors that are functionally impaired. Like J.CaM1, J.CaM3 demonstrates partial signal transduction via CD3/Ti to only certain stimuli. J.CaM1, J.CaM2, and J.CaM3 define three non-Ti complementation groups involved in receptor function. To evaluate the mutations further we have introduced a heterologous receptor, the human muscarinic receptor 1 (HM1), into the parental Jurkat and mutant cell lines. This receptor demonstrates signal transduction competence in all these hosts, indicating that 1) T cells express the necessary apparatus for the coupling of HM1 to second messenger generation and 2) the mutations in the J.CaM family all affect molecules that are specific to CD3/Ti, and not HM1, function. Finally, the HM1 receptor exhibits partial sensitivity to cholera toxin in Jurkat cells, in contrast to the virtually complete sensitivity of CD3/Ti to cholera toxin.

Antibodies, Monoclonal↗
PubMed1989

Ligand-induced association between the T-cell antigen receptor and two glycoproteins.

We have identified two cell surface glycoproteins of 34 and 38 kDa (gp34 and gp38) that associate with the T-cell antigen receptor (TCR). The coimmunoprecipitation of these proteins with the TCR is increased by treatment with monoclonal antibodies (mAbs) directed against the TCR prior to cell solubilization and immunoprecipitation. Treatment of T cells with mAbs directed against other cell surface molecules, CD2 or HLA, does not induce the association of these proteins with the TCR. The coimmunoprecipitation of gp34 and gp38 with the TCR requires solubilization in the presence of an alkylating agent, suggesting that subunit alkylation stabilizes the interaction. J.CaM1 and J.CaM2 are signal-transduction mutant cell lines derived from Jurkat. These cell lines fail to activate the inositol phospholipid second messenger pathway in response to anti-TCR mAbs. Treatment with mAb C305 (anti-TCR) induces the association of gp34 and gp38 with the TCR in J.CaM2 cells but not in J.CaM1. J.CaM1 modulates the TCR normally in response to anti-TCR antibody treatment. This observation suggests that gp34 and gp38 are involved in the signal-transduction pathway of the TCR complex rather than receptor internalization. Furthermore, since these proteins do associate with the TCR of J.CaM2, the induced association with the TCR is not a consequence of signal transduction.

Antibodies, Monoclonal↗
PubMed1989

Molecular characterization of a Leydig cell tumor presenting as congenital adrenal hyperplasia.

We present an unusual patient with a Leydig cell tumor to show that greatly elevated serum concentrations of 17-hydroxyprogesterone (17OHP) may not be diagnostic of congenital adrenal hyperplasia (CAH). A 3.5-yr-old boy had a small testicular mass and plasma 17OHP concentrations of 147-333 nmol/L (4,850-11,000 ng/dL), suggesting CAH with adrenal rests. However, normal plasma cortisol values and the unresponsiveness of the 17OHP concentration to dexamethasone suppression or ACTH stimulation suggested a diagnosis of Leydig cell tumor. A 4-fold elevation in plasma 21-deoxycortisol compared with a 200-fold elevation in 17OHP suggested that the elevated 17OHP derived from the normal pathway of testosterone synthesis in the testis. This was proven by normalization of all hormonal values after tumor resection. Compared to the abundance of mRNA for P450c17, the tumor contained unusually large amounts of mRNA for P450scc, the cholesterol side-chain cleavage enzyme, which is the rate-limiting step in steroid hormone synthesis. Increased P450scc activity, which increased the conversion of cholesterol to pregnenolone, apparently permitted the 17,20-lyase activity of P450c17 to become rate limiting, thus accounting for the increased secretion of 17OHP. Thus, Leydig cell tumors can produce quantities of 17OHP previously reported only in CAH due to 21-hydroxylase deficiency. The molecular characterization of steroidogenic mRNAs in this tumor indicates an unusual ratio in the expression of the genes for the steroidogenic enzymes, probably accounting for the unusual pattern of serum steroids.

17-Ketosteroids↗
PubMed1988

The CD2 ligand LFA-3 activates T cells but depends on the expression and function of the antigen receptor.

The T cell Ag receptor (CD3/Ti) and the sheep E receptor (CD2) expressed on the surface of human T cells are both capable of initiating intracellular signals necessary for T cell activation. CD3/Ti interacts with Ag to initiate cellular immune responses. Although the exact function of CD2 is unknown, lymphocyte function-associated Ag 3 (LFA-3), a 55- to 70-kDa receptor expressed on a broad spectrum of hemopoietic and nonhemopoietic cells, has recently been shown to be its natural ligand. We show here that although purified multimeric LFA-3 is not capable of initiating transmembrane signaling events on its own, the combination of LFA-3 and the anti-CD2 mAb CD2.1 induces intracellular calcium increases, phosphatidylinositol second messenger generation and lymphokine secretion in the T cell leukemic line Jurkat. In order to study the signaling requirements of CD2, we compared the ability of CD2 mAb and LFA-3 to initiate activation signals in Jurkat and in three Jurkat-derived mutants. A CD3-CD2+ mutant failed to increase calcium or exhibit phosphatidylinositol hydrolysis to either the combination of agonist CD2 mAb 9-1 and 9.6 or LFA-3 and CD2.1. Reconstitution of the Ag receptor by transfection of the Ti-beta-chain restored the expression of the CD3/Ti complex and the ability to respond to either combination of CD2 ligands. However, no response to CD2 ligands was detected in a CD3+CD2+ mutant selected for signaling defects to CD3/Ti ligands. Complementation of the CD3/Ti signaling defect by cell fusion also restored competency to respond to CD2 agonists. These results demonstrate that LFA-3 under appropriate conditions can activate T cells via the CD2 complex and that this activation requires not only the cell surface expression of the CD3/Ti complex but also a functional Ag receptor pathway.

Adjuvants, Immunologic↗
PubMed1988

Early signal transduction by the antigen receptor without commitment to T cell activation.

The T lymphocyte antigen-receptor complex mediates antigen-specific cell activation, at least in part, through the production of inositolphospholipid-derived second messengers. Little is known about how second messenger events, typically measured within minutes of ligand binding, eventually lead to distal biologic responses such as expression of lymphokine genes. Several monoclonal antibodies directed against the receptor complex were tested for their ability to elicit transmembrane signaling in the parental Jurkat line and in a somatic mutant (J.CaM1) with a deficient receptor function. One antibody elicited substantial early Ca2+ mobilization responses in both cells but was unable to promote expression of the interleukin-2 gene in J.CaM1. In J.CaM1 there was a diminished production of phosphatidylinositol second messengers, and the elevation in intracellular free Ca2+ was transient. Thus, short-term Ca2+ mobilization does not always indicate complete signal transmission and lead to a full cellular response.

Calcium↗
PubMed1988

Function of the antigen receptor in T cell activation.

The studies described here, including ours and those of others, were aimed at understanding the mechanism(s) by which the T cell antigen receptor transmits signals that result in expression of lymphokine genes. They have focused both on the proximal molecules and biochemical events that account for transmembrane signalling, as well as on the more distal nuclear regulatory events. It is now clear that the receptor is coupled to the PI pathway, apparently via conformational changes in Ti, possibly amplification by CD3, and likely a G protein. PI second messengers appear to contribute to subsequent gene expression events, but may not be required for receptor down-regulation. How these biochemical events are coupled to gene expression still remains a mystery. However, studies of the regulation of the IL-2 gene indicate that the proximal receptor-mediated events must occur continuously for 2-4 hours to support transcriptional activation of the IL-2 gene, and that protein synthesis during this time is required. Other genes, such as the proto-oncogene c-fos, become transcriptionally active within 15 minutes of receptor triggering even in the presence of protein synthesis inhibitors. Thus, coupling of the proximal biochemical events to expression of the IL-2 gene may be dependent on the induction of a regulatory protein(s). This protein(s) may act to activate the IL-2 gene via a 275 bp segment that lies upstream of the IL-2 coding region. Studies are now in progress to understand better the molecular requirements for competence in signal transduction and conversion of these signals into gene expression events.

Animals↗
PubMed1988

At least two non-antigen-binding molecules are required for signal transduction by the T-cell antigen receptor.

In the T-cell somatic mutant J.CaM1, the T-cell antigen receptor complex is poorly coupled to the inositolphospholipid second messenger system; some antibodies against the invariant CD3 subunit of the receptor retain their agonist function in J.CaM1. Here we show by a combination of complementation assays that the mutation in J.CaM1 affects a molecule other than the antigen-binding Ti subunit, suggesting that Ti is coupled indirectly to the signal transduction apparatus through a pathway involving the CD3 complex. We also describe another mutant, J.CaM2, in which the receptor complex is completely uncoupled from inositolphospholipid hydrolysis. J.CaM2 defines an additional complementation group, suggesting that signal transduction by the antigen receptor depends on at least two molecules distinct from Ti.

Calcium↗
PubMed1987

Isolation and characterization of a T-lymphocyte somatic mutant with altered signal transduction by the antigen receptor.

We have developed an approach for deriving and characterizing antigen-receptor (CD3/Ti) signal-transduction mutants. This strategy combines receptor-mediated growth inhibition and fluorescence-activated cell sorting with the Ca2+-indicator indo-1. Despite the expression of structurally normal CD3/Ti complexes, one such mutant (J.CaM1) fails to exhibit inositolphospholipid metabolism or Ca2+ mobilization in response to anti-CD3 or anti-Ti monoclonal antibodies and fails to produce lymphokines in response to these antibodies. Surprisingly, anti-Ti antibody retains its effectiveness as a stimulus for the down-regulation of CD3/Ti surface expression. These cells remain responsive to AIF-4, at least one anti-CD3 antibody, and some combinations of nonagonist anti-Ti and anti-CD3 antibodies. The mutation in J.CaM1 appears to lie in a proximal component of the signal-transduction apparatus.

Antigens, Differentiation, T-Lymphocyte↗
PubMed1987

Alterations in protein transport events in rat liver after estrogen treatment.

The effects of 17 alpha-ethynylestradiol (EE) treatment on the hepatic processing of rat polymeric immunoglobulin A (IgA) and human asialoorosomucoid (ASOr) were studied. After 5 days of treatment with EE (5 mg/kg) or solvent alone, male rats were anesthetized and injected with tracer doses of the test proteins. Bile flow rates had been reduced by greater than 60% in the EE-treated animals. A previously reported radiolabeling strategy was used to monitor both the transport of intact protein to bile and the degradation of protein in lysosomes. Transport of intact IgA to bile was reduced by 43%, with transport peaking 27 min later in EE-treated animals compared with controls. There was a corresponding impairment of uptake of labeled IgA from blood. EE induced no kinetic change in the uptake or processing of ASOr. However, there was an increase in the proportion of ASOr reaching bile intact from 3% to 15-23% of the injected dose. The data indicate that EE disables the transport pathway for IgA and causes a partial change in the routing of ASOr after endocytosis in favor of direct transport to the bile canaliculus. These findings may have implications for the importance of membrane composition in protein transport events.

Animals↗
PubMed1987

The activation of T lymphocytes.

The events involved in T cell activation are initiated at the cell surface by the interaction of ligands with specific cell surface receptors on the T cell. Central to antigen-induced activation is the CD3/Ti complex, a complex multi-chain receptor responsible for antigen/MHC recognition and signal transduction. Triggering the CD3/Ti complex results in the generation of intracellular second messengers, IP3 and DG, which are derived from PI metabolism. The second messengers lead to increases in [Ca2+]i and activation of pkC, events causally linked to various cellular responses, including the production of IL-2 through as yet poorly defined pathways. Little is known about how other cell surface molecules that may provide an accessory function participate in such events. However, future genetic and biochemical studies are likely to shed light upon the mechanisms of signal transduction by the CD3/Ti complex and accessory molecules and the details of the intracellular events involved in the activation of a host of cellular genes associated with activation.

Animals↗
PubMed1984

Phase I study of mitoxantrone on a daily X 5 schedule.

Mitoxantrone (NSC-301739) is a synthetic amino anthraquinone DNA intercalater active in several experimental tumor systems. Thirty-three patients with advanced cancer received the drug on a daily X 5 schedule. Myelosuppression, especially leukopenia, was the dose-limiting toxicity and was reversible. Nausea and vomiting occurred sporadically. No definite hepatic, renal, or cardiac toxicities were noted. The recommended dose for phase II evaluation in solid tumor patients with little or no prior therapy is 4.2 mg/m2/day X 5. Patients with prior myelosuppressive therapy but adequate bone marrow reserve may be started at 2.6 mg/m2/day X 5.

Adult↗
PubMed1983

Phase I study of L-alanosine (NSC 15353).

L-alanosine (NSC 15353) is a newly developed antitumor antibiotic which acts as an inhibitor of purine intermediary metabolism. Experimental antitumor activity was demonstrated in a variety of murine neoplasms. A Phase I trial was undertaken on a daily x 5 (d x 5) schedule in 22 evaluable patients. Dose limiting toxicity was an oral mucositis characterized by beefy red oral, lingual and pharyngeal erythema. The maximum tolerated dose is 320 mg/m2/d x 5 every three weeks. The recommended dose for Phase II evaluation is 160 mg/m2/d x 5 every three weeks.

Adult↗
PubMed1983

Kaposi's sarcoma in a young homosexual man. Association with angiofollicular lymphoid hyperplasia and a malignant lymphoproliferative disorder.

Recent reports have described an unexpected number of cases of a virulent form of a Kaposi's sarcoma (KS) as well as acquired immunodeficiency in young homosexual men. A 31-year-old man initially had a benign disorder, angiofollicular lymphoid hyperplasia. Kaposi's sarcoma then developed, and he died of a malignant lymphoproliferative disorder. We believe that this is unique among the recently described cases of KS in homosexual men because of the occurrence of this second malignancy. It may be that similar cases will be recognized in this population.

Adult↗